4-氯-1,5-二氮杂萘-3-甲腈 | 305371-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-氯-1,5-二氮杂萘-3-甲腈
• 中文别名: 4-氯-1,5-萘啶-3-甲腈
• 英文名称: 4-chloro-1,5-naphthyridine-3-carbonitrile
• CAS: 305371-02-2
• 化学式: C₉H₄ClN₃
• 分子量: 189.604
• InChiKey: LBJBQKHZRGKNME-UHFFFAOYSA-N

物化性质

• 沸点：
  364.7±37.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氯-1,5-二氮杂萘-3-甲腈 、 9,9-二甲基吖啶 在 palladium diacetate 、 sodium t-butanolate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 甲苯 为溶剂， 反应 48.0h， 以45%的产率得到4-(9,9-dimethyl-9,10-dihydroacridine)-1,5-naphthyridine-3-carbonitrile
  参考文献：
  名称：

  基于萘啶的发射体同时显示出热激活的延迟荧光和聚集诱导的发射，从而实现了高效的非掺杂荧光OLED †

  摘要：

  高效的非掺杂有机发光二极管（OLED）迫切需要同时具有出众的发光效率，固态的热激活延迟荧光（TADF）和聚集诱导发射（AIE）特性的发光材料。这里有两个新的发射器，即ND-AC和CND-AC以萘啶或氰基萘啶链段为电子受体，以unit啶单元为电子供体，对其进行了设计，合成和研究。目标发射体的近乎正交的分子构型不仅使它们在单重态和三重态之间具有较小的能量差，从而确保了TADF特性，而且还具有显着的AIE功能。由于高的光致发光量子产率，以及出色的TADF和AIE特性，基于ND-AC的掺杂和非掺杂OLED均具有出色的性能，其最大外部量子效率分别为16.8％和12.0％。这些结果表明，基于萘啶的发射体在OLED中具有广阔的应用前景。

  DOI：

  10.1039/c9tc00346k
• 作为产物：
  描述：

  4-hydroxy-1,5-naphthyridine-3-carbonitrile 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 3.0h， 以33%的产率得到4-氯-1,5-二氮杂萘-3-甲腈
  参考文献：
  名称：

  基于萘啶的发射体同时显示出热激活的延迟荧光和聚集诱导的发射，从而实现了高效的非掺杂荧光OLED †

  摘要：

  高效的非掺杂有机发光二极管（OLED）迫切需要同时具有出众的发光效率，固态的热激活延迟荧光（TADF）和聚集诱导发射（AIE）特性的发光材料。这里有两个新的发射器，即ND-AC和CND-AC以萘啶或氰基萘啶链段为电子受体，以unit啶单元为电子供体，对其进行了设计，合成和研究。目标发射体的近乎正交的分子构型不仅使它们在单重态和三重态之间具有较小的能量差，从而确保了TADF特性，而且还具有显着的AIE功能。由于高的光致发光量子产率，以及出色的TADF和AIE特性，基于ND-AC的掺杂和非掺杂OLED均具有出色的性能，其最大外部量子效率分别为16.8％和12.0％。这些结果表明，基于萘啶的发射体在OLED中具有广阔的应用前景。

  DOI：

  10.1039/c9tc00346k

文献信息

• 一种荧光材料、制备方法及应用
  申请人：深圳大学

  公开号：CN109836422B

  公开（公告）日：2022-03-18

  本发明公开了一种荧光材料、制备方法及应用，其中，荧光材料的分子结构通式如下：R1～R6各自独立地选自H原子、氘原子、给电子基团或拉电子基团中的一种；并且R1～R6至少有一个是给电子基团，至少有一个是拉电子基团。本发明提供的荧光材料，具有扭曲的D(Donor)‑A(Acceptor)结构，同时具有热活化延迟荧光和聚集诱导发光特性，既可以实现100％的内量子效率，又能减少聚集导致的发光猝灭过程。将这些材料用作掺杂和非掺杂有机电致发光器件发光层中的发光客体时，其效率可与磷光相媲美，并且避免了现有的磷光材料通常要使用重金属铱、铂等昂贵的重金属的问题，降低了成本。
• Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
  申请人：American Cyanamid Company

  公开号：US20020165229A1

  公开（公告）日：2002-11-07

  This invention provides compounds of formula I having the structure 1 wherein: X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or X is pyridinyl, pyrimidinyl, or Ph; or X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms, where the bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S; wherein the bicyclic aryl or bicyclic heteroaryl ring may be optionally mono-, di-, tri-, or tetra-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or X is the radical 2 ; E is pyridinyl, pyrimidinyl, or Ph; T is substituted on E at carbon and is —NH(CH 2 ) m —, —O(CH 2 ) m —, —S(CH 2 ) m —, —NR(CH 2 ) m —, —(CH 2 ) m —(CH 2 ) m NH—, —(CH 2 ) m O—, —(CH 2 ) m S—, or —(CH 2 ) m NR—; L is a Ph; or L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3 heteroatoms selected from N, O, and S; wherein the heteroaryl ring may be optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; Pyridinyl, pyrimidinyl, or Ph are pyridinyl, pyrimidinyl, or phenyl radicals, respectively, which may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, benzoyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; Z is —NH—, —O—, —S—, or —NR—; R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms; A″ is a diavalent moiety selected from the group 3 G 1 , G 2 , G 3 , and G 4 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 2-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 49 carbon atoms, alkynoyloxymethyl of 49 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino, R 2 NH, 4 R 7 —(C(R 6 ) 2 ) g —Y—, R 7 —(C(R 6 ) 2 ) p —M—(C(R 6 ) 2 ) k —Y—, Het-(C(R 6 ) 2 ) q —W—(C(R 6 ) 2 ) k —Y—, with the proviso that G 3 and G 4 are not R 2 NH; Y is a divalent radical selected from the group consisting of 5 R 7 is —NR 6 R 6 , —OR 6 , —J, —N(R 6 ) 3 + , or —NR 6 (OR 6 ); M is >NR 6 , —O—, >N—(C(R 6 ) 2 ) p NR 6 R 6 , or >N—(C(R 6 ) 2 ) p —OR 6 ; W is >NR 6 , —O— or is a bond; Het is a heterocyclic radical selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydropyran, and 6 which may be optionally mono- or di-substituted on carbon with R 6 , hydroxy, —N(R 6 ) 2 , —OR 6 —(C(R 6 ) 2 ) s OR 6 or —(C(R 6 ) 2 ) s N(R 6 ) 2 ; optionally mono-substituted on nitrogen with R 6 ; and optionally mono or di-substituted on a saturated carbon with divalent radicals —O— or —O(C(R 6 ) 2 ) s O—; R 6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl 2-7 carbon atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom; R 2 , is selected from the group consisting of 7 R 3 is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, 8 , R 7 —(C(R) 2 ) s —, R 7 —(C(R 6 ) 2 ) p —M—(C(R 6 ) 2 ) r —, R 8 R 9 —CH—M(C(R 6 ) 2 ) r —, or Het-(C(R 6 ) 2 ) q —W—C(R 6 ) 2 ) r —; R 5 is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, 9 , R 7 —(C(R 6 ) 2 ) s —, R 7 —(C(R 6 ) 2 ) p —M—(C(R 6 ) 2 ) r —, R 8 R 9 —CH—M—(C(R 6 ) 2 ) r —, or Het-(C(R 6 ) 2 ) q —W—(C(R 6 ) 2 ) r —; R 8 , and R 9 are each, independently, —(C(R 6 ) 2 ) r NR 6 R 6 , or —(C(R 6 ) 2 ) r OR 6 ; J is independently hydrogen, chlorine, fluorine, or bromine; Q is alkyl of 1-6 carbon atoms or hydrogen; a=0-1; g=1-6; k=0-4; n is 0-1; m is 0-3; p=2-4; q=0-4; r=1-4; s=1-6; u=0-4 and v=0-4, wherein the sum of u+v is 2-4; or a pharmaceutically acceptable salt thereof, provided that when R 6 is alkenyl of 2-7 carbon atoms or alynyl of 2-7 carbon atoms, such alkenyl or alynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom; and provided that when R 3 is bound to sulfur, it cannot be hydrogen, carboxy, carboalkoxy, or carboalkyl; and provided that when Y is —NR 6 — and R 7 is —NR 6 R 6 , —N(R 6 ) 3 + , or —NR 6 (OR 6 ), then g=2-6; when M is —O— and R 7 is —OR 6 then p=1-4; when Y is —NR 6 — then k=2-4; when Y is —O— and M or W is —O— then k=1-4 when W is not a bond with Het bonded through a nitrogen atom then q=2-4 and when W is a bond with Het bonded through a nitrogen atom and Y is —O— or —NR6— then k=2-4; and finally provided that when A″ is the moiety 10 n=0, Z is NH, G 1 is hydrogen, halogen, alkyl, alkoxy, hydroxy, alkanoyloxy of 2-6 carbon atoms, or phenoxy, and G 2 is hydrogen, halogen, alkyl, hydroxy, carboxyalkyl, carboalkoxyalkyl, hydroxyalkyl, alkoxy,halomethyl, carboxyl, carboalkoxy, alkanoylamino, or alkenoylamino, then X can not be a pyridinyl, pyrimidinyl, or phenyl ring that is substituted with a hydroxy or alkoxy group, which are useful as inhibitors of protein tyrosine kinase.

  本发明提供了具有以下结构的公式I的化合物：其中：X是3到7个碳原子的环烷基，可以选择地用1到6个碳原子的烷基取代；或者X是吡啶基、嘧啶基或苯基；或者X是8到12个原子的双环芳基或双环杂芳基环系，其中双环杂芳基环含有1到4个从N、O和S中选择的杂原子；其中双环芳基或双环杂芳基环可以选择地单、双、三或四取代，取代基选择自卤素、氧代、硫代、1-6个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、偶氮基、1-6个碳原子的羟基烷基、卤代甲基、2-7个碳原子的烷氧甲基、2-7个碳原子的烷酰氧甲基、1-6个碳原子的烷氧基、1-6个碳原子的烷硫基、羟基、三氟甲基、氰基、硝基、羧基、2-7个碳原子的羧酸酯基、2-7个碳原子的羧基烷基、苯氧基、苯基、噻吩氧基、苯甲酰基、苄基、氨基、1-6个碳原子的烷基氨基、2到12个碳原子的二烷基氨基、苯基氨基、苄基氨基、1-6个碳原子的烷酰氨基、3-8个碳原子的烯酰氨基、3-8个碳原子的炔酰氨基、2-7个碳原子的羧基烷基、3-8个碳原子的羧酸酯基烷基、1-5个碳原子的氨基烷基、2-9个碳原子的N-烷基氨基烷基、3-10个碳原子的N,N-二烷基氨基烷基、2-9个碳原子的N-烷基氨基烷氧基、3-10个碳原子的N,N-二烷基氨基烷氧基、巯基、甲硫基和苯甲酰氨基；或者X是基团2；E是吡啶基、嘧啶基或苯基；T在碳上被取代，为—NH(CH2)m—、—O(CH2)m—、—S(CH2)m—、—NR(CH2)m—、—(CH2)m—(CH2)mNH—、—(CH2)mO—、—(CH2)mS—或—(CH2)mNR—；L是苯基；或者L是一个5或6元杂芳基环，其中杂芳基环含有1到3个从N、O和S中选择的杂原子；其中杂芳基环可以选择地单取代或双取代，取代基选择自卤素、氧代、硫代、1-6个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、偶氮基、1-6个碳原子的羟基烷基、卤代甲基、2-7个碳原子的烷氧甲基、2-7个碳原子的烷酰氧甲基、1-6个碳原子的烷氧基、1-6个碳原子的烷硫基、羟基、三氟甲基、氰基、硝基、羧基、2-7个碳原子的羧酸酯基、2-7个碳原子的羧基烷基、苯氧基、苯基、噻吩氧基、苯甲酰基、苄基、氨基、1-6个碳原子的烷基氨基、2到12个碳原子的二烷基氨基、苯基氨基、苄基氨基、1-6个碳原子的烷酰氨基、3-8个碳原子的烯酰氨基、3-8个碳原子的炔酰氨基、2-7个碳原子的羧基烷基、3-8个碳原子的羧酸酯基烷基、1-5个碳原子的氨基烷基、2-9个碳原子的N-烷基氨基烷基、3-10个碳原子的N,N-二烷基氨基烷基、2-9个碳原子的N-烷基氨基烷氧基、3-10个碳原子的N,N-二烷基氨基烷氧基、巯基、甲硫基和苯甲酰氨基；Pyridinyl、pyrimidinyl或Ph分别是吡啶基、嘧啶基或苯基基团，可以选择地单、双或三取代，取代基选择自卤素、1-6个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、偶氮基、1-6个碳原子的羟基烷基、卤代甲基、2-7个碳原子的烷氧甲基、2-7个碳原子的烷酰氧甲基、1-6个碳原子的烷氧基、1-6个碳原子的烷硫基、羟基、三氟甲基、氰基、硝基、羧基、2-7个碳原子的羧酸酯基、2-7个碳原子的羧基烷基、苯甲酰基、氨基、1-6个碳原子的烷基氨基、2到12个碳原子的二烷基氨基、1-6个碳原子的烷酰氨基、3-8个碳原子的烯酰氨基、3-8个碳原子的炔酰氨基、2-7个碳原子的羧基烷基、3-8个碳原子的羧酸酯基烷基、1-5个碳原子的氨基烷基、2-9个碳原子的N-烷基氨基烷基、3-10个碳原子的N,N-二烷基氨基烷基、2-9个碳原子的N-烷基氨基烷氧基、3-10个碳原子的N,N-二烷基氨基烷氧基、巯基、甲硫基和苯甲酰氨基；Z是—NH—、—O—、—S—或—NR—；R是1-6个碳原子的烷基或2-7个碳原子的羧基烷基；A″是从群体3中选择的二价基团，G1、G2、G3和G4分别独立地是氢、卤素、1-6个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、2-6个碳原子的烯氧基、2-6个碳原子的炔氧基、羟甲基、卤代甲基、2-6个碳原子的烷酰氧基、3-8个碳原子的烯酰氧基、3-8个碳原子的炔酰氧基、2-7个碳原子的烷酰氧甲基、3-8个碳原子的烯酰氧甲基、3-8个碳原子的炔酰氧甲基、2-7个碳原子的烷氧甲基、1-6个碳原子的烷氧基、1-6个碳原子的烷硫基、1-6个碳原子的烷磺酰基、1-6个碳原子的烷磺酰胺基、2-6个碳原子的烯磺酰胺基、2-6个碳原子的炔磺酰胺基、羟基、三氟甲基、三氟甲氧基、氰基、硝基、羧基、2-7个碳原子的羧酸酯基、2-7个碳原子的羧基烷基、苯氧基、苯基、噻吩氧基、苄基、氨基、1-4个碳原子的烷氧基、1-6个碳原子的烷基氨基、2到12个碳原子的二烷基氨基、N-烷基氨基烷基、N,N-二烷基氨基烷基、4到12个碳原子的N-烷基-N-烯基氨基、6-12个碳原子的N,N-二烯基氨基、苯基氨基、苄基氨基、R2NH、R7—(C(R6)2)g—Y—、R7—(C(R6)2)p—M—(C(R6)2)k—Y—、Het-(C(R6)2)q—W—(C(R6)2)k—；但是当R6为2-7个碳原子的烯基或炔基时，该烯基或炔基通过饱和碳原子与氮或氧原子结合；当R3与硫结合时，它不能是氢、羧基、羧酸酯基或羧基烷基；当Y是—NR6—且R7是—NR6R6、—N(R6)3+或—NR6(OR6)时，g=2-6；当M是—O—且R7是—OR6时，p=1-4；当Y是—NR6—时，k=2-4；当Y是—O—且M或W是—O—时，k=1-4；当W不是与Het通过氮原子结合的键时，q=2-4；当W是与Het通过氮原子结合的键且Y是—O—或—NR6—时，k=2-4；最后，当A″是基团10时，n=0，Z是NH，G1是氢、卤素、烷基、烷氧基、羟基、2-6个碳原子的烷酰氧基或苯氧基，G2是氢、卤素、烷基、羟基、烷基羧酸、烷氧基、卤代甲基、羧基、羧酸酯基、1-6个碳原子的烷基酰胺基或3-8个碳原子的烯基酰胺基时，X不能是带有氢氧基或烷氧基取代的吡啶基、嘧啶基或苯基环，这些化合物可用作蛋白酪氨酸激酶的抑制剂。
• Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
  申请人：American Cyanamid Company

  公开号：US06355636B1

  公开（公告）日：2002-03-12

  This invention provides compounds of formula I having the structure useful as inhibitors of protein tyrosine kinase.

  这项发明提供了具有公式I结构的化合物，可用作蛋白酪氨酸激酶抑制剂。
• Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
  申请人：American Cyanamid Company

  公开号：US06548496B2

  公开（公告）日：2003-04-15

  This invention provides compounds of formula I having the structure Wherein substitutions at A″, Z, n, and X are set forth in the specification.

  该发明提供了具有以下结构的I型化合物，其中A″，Z，n和X的取代基在规范中列出。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Castro Alfredo C.

  公开号：US20130029982A1

  公开（公告）日：2013-01-31

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性（包括PI3激酶活性）的化合物和药物组合物，以及治疗与激酶活性（包括PI3激酶活性）相关的疾病和病情的化合物、药物组合物和治疗方法。